328 results about "Antigen epitope" patented technology

The invention belongs to the technical field of immunotherapy, and particularly relates to a monkey pox virus antigen epitope peptide and application thereof. The invention aims to solve the technical problem that at present, a T cell antigen epitope peptide for universal vaccines of monkey pox viruses is not developed in the field of monkey pox viruses. According to the technical scheme of the invention, the amino acid sequence of the monkey pox virus antigen epitope peptide is shown as SEQ ID No.2. The antigen epitope peptide provided by the invention has very strong immunogenicity, and can induce antigen-specific CD8 + T cells; the antibody can be directly loaded to antigen presenting cells, can activate T cells and effectively induce T cell immunity, and can be used for research and development and preparation of universal vaccines for monkey pox viruses, research and development of drugs and clinical treatment.

The present invention provides a rabies virus G protein antigen epitope targeting completely human monoclonal antibody and applications thereof, the completely human monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region has three complementary determining region amino acid sequences: GDISSSCFY, IHYSGST and ARHRRGYCYDSEKGGTNWFDP, and the light chain variable region has three complementary determining region amino acid sequences: GDISSSCFY, IHYSGST and ARHRRGYCYDSEKGGTNWFDP. The amino acid sequences of the three complementary determining regions of the light chain variable region are respectively as follows: QGISND, ATS and LQDYEFPLT. The fully human monoclonal antibody has efficient and broad-spectrum anti-rabies virus neutralizing activity, is high in expression, fully human-derived and good in stability, and can be used for preparing rabies virus detection products or drugs for preventing and treating rabies.

The invention provides an antigen epitope peptide related to connexin and application of the antigen epitope peptide. The connexin antigen epitope peptide disclosed by the invention is selected from (1) a polypeptide with an amino acid sequence as shown in SEQ ID NO: 14; and (2) a polypeptide which is derived from (1) by substituting, deleting or adding 1-2 amino acids in the amino acid sequence of SEQ ID NO: 14 and retains the binding capacity with a connexin antibody. According to the present invention, the new connexin antigenic peptide fragment sequence is identified for the first time, such that the existing autoantigen epitope map is expanded, and more importantly, the molecular basis is provided for the development of the clinical detection method with high diagnosis sensitivity and high specificity, such that the pathological mechanism of MG can be further improved, and the application prospect is broad. And new auxiliary diagnosis means and treatment targets are provided for antibody negative MG patients.

The invention discloses a porcine reproductive and respiratory syndrome virus M protein antigen epitope peptide and a monoclonal antibody thereof. The amino acid sequence of the antigen epitope peptide is as shown in SEQ ID No. 11; the heavy chain variable region of the monoclonal antibody comprises CDR1-3 as shown in SEQ ID No.1 to SEQ ID No.3; the light chain variable region comprises CDR1-3 as shown in SEQ ID No. 4 to 6; the monoclonal antibody reacts with a plurality of PRRSV strains such as HP-PRRSV, NADC30PRRSV, NADC34PRRSV and the like, and the conservative property is good; the antibody can be obtained by biological means such as conventional genetic engineering, and the problem that the genetic sequence of the antibody is easy to lose due to long-term cryopreservation of traditional hybridoma cells is avoided; optimization of the antibody on the gene or protein level is facilitated, and the specificity and affinity of the antibody are further improved.

The invention provides a disease marker epitope prediction and antibody screening method, which belongs to the technical field of disease markers, and comprises the following steps: firstly, establishing a training data set containing a known antigen-antibody compound structure and disease tissue expression data; and obtaining target protein sequence information through liquid chromatography-mass spectrometry analysis and carrying out sequence comparison. And then a deep convolutional neural network is utilized to extract sequence features, and surface exposure sites are identified by combining secondary structure prediction and solvent accessibility analysis. After the features are integrated with sequence evolution conservative properties, a prediction model is constructed by using a random forest classifier. The method comprises the following steps: carrying out molecular dynamics simulation on a prediction result, screening first 10% of candidate sequences through a comprehensive scoring function and K-means clustering, and finally determining an antigen epitope sequence with the strongest binding activity through verification of an antigen chip and a fluorescence labeled antibody system, so that the technical problem that specific antigen epitopes are difficult to accurately predict and recognize in the prior art is solved.

The invention discloses a surface antigen gene StSAG1 of Sarcocystis tenella, the nucleotide sequence of the surface antigen gene StSAG1 is as shown in SEQ ID NO: 1, and according to the analysis result of protein antigenicity and antigen epitope, the 686 bp-1175 bp segment of the StSAG1 gene is selected to construct a recombinant protein expression vector and engineering bacteria; the antigen disclosed by the invention has very strong antigenicity and specificity, and can be subjected to effective antigen-antibody reaction with an antibody generated in serum after sheep (Ovis aries) is infected with sarcosporidium tenella, so that diagnosis is realized; low-titer antibodies can be detected two weeks after infection, and the detection window period is obviously advanced; by adopting the ELISA detection method, a visual result can be directly obtained. The method breaks through the limitation of an infection window period, has the advantages of low cost, high sensitivity, simplicity and convenience in operation, no need of expensive instruments and analysis and the like, is suitable for field detection in primary laboratories and pastures, and is beneficial to industrial production and market popularization and application.

The invention belongs to the technical field of tumor vaccines, and particularly relates to an mRNA (messenger Ribonucleic Acid) vaccine for coding tumor antigen epitopes as well as a preparation method and application thereof. In order to overcome the defect of immune escape caused by insufficiency or loss of a single antigen, the invention provides an mRNA vaccine capable of simultaneously coding a plurality of tumor antigen epitopes, and the tumor antigen epitopes are selected from high-frequency mutation epitopes of human tumor driving genes, such as G12D, G12V and G12C mutations of RAS genes; the antigenic epitopes can be used for preparing antigenic epitopes related to common viruses of human tumors, such as HPV16E6 / E7, EBV LAMP1 or CMV pp65, and tumor high-expression carcino-embryonic antigen gene epitopes, such as MAGE-A4, NY-ESO-1, WT1, and the like. The mRNA vaccine is obtained by serially expressing a plurality of tumor antigen epitopes and encapsulating and delivering lipid nanoparticles. Experiments prove that the compound can effectively prevent and treat various tumors and has a wide application prospect.

The invention relates to the field of immunology, and particularly discloses a hepatitis B virus specific TCR combination and application, the hepatitis B virus specific TCR combination is used for recognizing HBV antigen epitopes, the hepatitis B virus specific TCR combination comprises a plurality of separated TCRs, the plurality of separated TCRs form two TCR groups, and the two TCR groups comprise a first TCR group and a second TCR group; wherein the first TCR group specifically recognizes a first antigen epitope, and the amino acid sequence of the first antigen epitope is as shown in SEQ ID NO: 1; the first TCR group specifically recognizes a first antigen epitope, the second TCR group specifically recognizes a second antigen epitope, the amino acid sequence of the second antigen epitope is shown as SEQ ID NO: 2, the second antigen epitope respectively and correspondingly recognizes different antigen epitopes, the hepatitis B virus specific TCR and the epitope thereof are screened out, and an important means can be provided for treatment of TCR-T immune cells infected by hepatitis B virus.

The present invention relates to the technical field of biomedicine. Specifically provided are a respiratory syncytial virus (RSV) Pre-F recombinant protein nanoparticle vaccine and a preparation method therefor. By performing amino acid mutation on an RSV Pre-F protein, and performing fusion expression on the mutated Pre-F protein and ferritin particles in eukaryotic cells, PreF-Ferritin fusion protein nanoparticles, in which eight Pre-F protein trimers are densely displayed on the surface of each ferritin particle, are obtained. By stabilizing and exposing antigen epitopes required to be displayed and disrupting or masking unrequired antigen epitopes, the PreF-Ferritin fusion protein nanoparticles effectively improve the immunogenicity and the production stability of the antigen. Experiments show that: when the PreF-Ferritin fusion protein is injected into mice, high-titer protective sera can be acquired, and the mice sera can yield relatively high neutralizing titers against RSV.

The invention discloses a porcine delta coronavirus spike protein monoclonal antibody, an antigen epitope peptide and application, and belongs to the technical field of biology. The antibody comprises a light chain variable region and a heavy chain variable region, the amino acid sequence of the light chain variable region is as shown in SEQ ID No.1, and the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No.3. According to the invention, a highly conservative linear B cell epitope (the amino acid sequence is DFGEARLD) of a PDCoV spike protein receptor binding domain (S-RBD) and a neutralizing monoclonal antibody capable of being specifically bound to the epitope are identified for the first time. The epitope peptide and the monoclonal antibody provided by the invention can be used for immunological detection and serological investigation of the PDCoV.

The invention belongs to the technical field of gene editing, and discloses a fusion protein, a base editing system for realizing protein multimerization and application. The fusion protein provided by the invention is a Cas9 protein in which antigen epitopes are embedded or replaced; the antigen epitope is an antigen epitope in a protein collection system; the antigen epitope can realize multimerization of the fusion protein. The base editor system comprises the fusion protein and an editing enzyme fusion protein. The editing enzyme fusion protein comprises an antibody of the antigen epitope and editing enzyme. The base editor system disclosed by the invention has the characteristics of a base editing platform which can be modularized, multimerized, programmable and extensible, and brings more possibilities and selection capabilities to the field of gene editing. The base editor system can be applied to gene editing, including application in the fields of basic research, gene therapy, animal living body editing, agricultural breeding and the like.

The invention discloses recombinant humanized XVII type and recombinant humanized I type collagen sequences as well as a synthesis method and application thereof, the recombinant humanized collagen comprises one or more functional sequences in cell integrin binding sites such as R / KGD, GER / K, GVMGFP and DGEA, the molecular weight is 6-14 kDa, and the recombinant humanized collagen simultaneously surrounds an isoelectric point, has hydrophilicity and hydrophobicity, and can be used for preparing the recombinant humanized collagen. Reasonable design is carried out on information such as an antigen epitope, GXY sequence stability, protease degradation sites and the like, so that the recombinant humanized collagen has relatively good stability and also has biological activity of promoting cell proliferation and resisting wrinkles and tightening.

The invention belongs to the technical field of molecular biology, and particularly discloses a specific nano antibody targeting bovine TLR7 protein as well as a screening method and application of the specific nano antibody. The nano antibody can be specifically combined with a B cell antigen epitope of bovine TLR7 protein, and the B cell antigen epitope is selected from SEQ ID NO: 1 and / or SEQ ID NO: 2. The invention discloses a specific nano antibody targeting bovine TLR7 protein as well as a screening method and application of the specific nano antibody. The specific nano antibody targeting bovine TLR7 protein is high in stability and specificity and has super-strong affinity.

The invention discloses an ILTV gD protein antigen epitope expression cassette, a recombinant virus and application, and relates to the field of gene and protein engineering. The ILTV gD protein antigen epitope expression cassette provided by the invention comprises T and B cell epitopes of gD protein derived from an infectious laryngotracheitis virus WG strain. The recombinant virus rH120-gD-T / B is obtained by replacing a 5ab gene of an infectious bronchitis virus H120 strain with a gene for coding an ILTV gD protein antigen epitope expression cassette. The recombinant virus has good genetic stability, can be used for developing a safe and effective IB-ILT bivalent live vector vaccine, and solves the problem of poor stability of the current recombinant IBV.

The invention provides a portunus trituberculatus SCP antigen, antibody, kit and application, and belongs to the technical field of allergen detection. The antigen of the portunus trituberculatus SCP comprises an antigen epitope peptide of the portunus trituberculatus SCP and a carrier protein, and the amino acid sequence of the antigen epitope peptide of the portunus trituberculatus SCP is as shown in SEQ ID NO. 14. The antigen epitope peptide of the antigen portunus trituberculatus SCP has a relatively stable structure before and after thermal processing, the detection limit of an antibody prepared from the antigen for detecting a crustacean allergen is 0.32 mu g / mL, the quantitation limit is 1.06 mu g / mL, the crustacean allergen can be specifically detected, and the antibody can be used for detecting the crustacean allergen. In addition, when the antibody is used for detecting the crustacean allergen, the accuracy is good, the matrix interference resistance and the precision are high, and the high detection effect on the crustacean allergen in food processed at high temperature can still be kept.

The invention belongs to the technical field of biological detection, and particularly relates to a specific monoclonal antibody for AKK bacterium active protein P9, a detection kit and application of the specific monoclonal antibody. The antibody pair is 7G4 and 8B2, the amino acid sequence of a heavy chain variable region of the 7G4 is SEQ ID NO.2, and the amino acid sequence of a light chain variable region of the 7G4 is SEQ ID NO.4; the amino acid sequence of the 8B2 heavy chain variable region is SEQ ID NO.6, and the amino acid sequence of the 8B2 light chain variable region is SEQ ID NO.8. The antibody pair has strong specificity and high affinity, and can accurately recognize different antigen epitopes of the P9 protein. A colloidal gold detection and double-antibody sandwich ELISA detection system constructed based on the kit adapts to a complex matrix and various process treatment samples, is stable and reliable in detection, has qualitative and quantitative capabilities, can be used for scenes of P9 protein detection, fermentation monitoring, quality control and the like, and solves the problems of insufficient specificity, poor adaptability and the like in the prior art.

The invention discloses a paralichthys olivaceus rhabdovirus G protein tandem antigen epitope peptide and application thereof, and belongs to the field of fish molecular immunology. The amino acid sequence of the tandem antigen epitope peptide is shown as SEQ ID NO: 1. The preparation method comprises the following steps: (1) firstly, analyzing structural characteristics of HIRRV-G protein, predicting B cell antigen epitopes of the HIRRV-G protein, screening the antigen epitopes with advantages on the basis of a prediction result, and synthesizing the antigen epitopes; (2) screening a candidate peptide fragment with high affinity through an enzyme-linked immunosorbent assay; and (3) sequentially connecting the high-affinity peptide fragment sequences meeting the requirements by using a GPGPG connexon, cloning the connected sequences into a pET-28a prokaryotic expression vector, and performing induced expression to obtain the tandem antigen epitope peptide. Compared with a full-length G protein, the tandem antigen epitope peptide is smaller in molecular weight, higher in stability and higher in hydrophilicity; a large number of specific antibodies can be induced in fish bodies, and the death rate of the paralichthys olivaceus infected by viruses is remarkably reduced. The method can be used for HIRRV diagnosis detection reagent and subunit vaccine development.

The invention discloses an addiction-related epitope intelligent prediction and antibody optimization design method, and belongs to the field of medicine.The design method specifically comprises the following steps that firstly, multi-source heterogeneous biological information data are integrated, and the potential space structure, dynamic stability and regulation and control characteristics of an epitope are extracted; iI, identifying a low-immunogenicity region in the addiction target, and generating a high-adaptability candidate epitope according to the identified low-immunogenicity region; iII, optimizing antibody design according to the high-adaptability candidate epitopes, and dynamically adjusting the antibody design according to real-time molecular dynamics simulation feedback; according to the method, double optimization of antibody affinity and safety can be realized, the design efficiency and accuracy are improved, the problems of blind screening and low-efficiency verification in a traditional method are avoided, and the recognition redundancy of the antibody is improved, so that the effective period of a drug is prolonged, and the off-target risk is reduced.

The invention discloses a multi-epitope peptide of novel coronavirus, a vaccine as well as a preparation method and application of the multi-epitope peptide, and belongs to the technical field of preparation of polypeptide vaccines. The multi-epitope peptide of the novel coronavirus not only contains T cell epitopes, but also contains B cell epitopes, and can induce humoral immunity and cellular immunity responses of an organism at the same time; the vaccine comprises epitopes from four antigenic proteins of novel coronavirus, and can induce comprehensive immune response. According to the multi-epitope peptide vaccine based on the novel coronavirus, the nano-carrier KFE8 serves as a delivery carrier, different antigen epitopes of the same pathogen or antigen epitopes of different pathogens can be presented in a mixed mode, safety is good, large-scale rapid preparation is achieved in an emergency state, and the vaccine is suitable for large-scale popularization and application. The coronavirus vaccine is a novel coronavirus universal vaccine which can cover various pathogen subtypes and induce broad-spectrum and long-term immune effects.

The application provides a cell fixing solution for a myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) and a product and application thereof, and relates to the technical field of in-vitro detection. The cell fixing solution provided by the application is composed of polyoxymethylene, formaldehyde, acetic acid, raffinose and a buffer solution, can effectively fix the cell morphology, maximally retains the natural spatial conformation and antigen epitope integrity of myasthenia gravis related antigens AChR, Titin, RyR1, MuSK and LRP4, reduces the problems of antigen denaturation, epitope shielding and protein loss in the fixing process, can efficiently and accurately realize the synchronous joint detection of various specific antibodies, and the myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) prepared by the application has stable detection results, and has important clinical application value and industrial popularization prospect.

The invention relates to the technical field of genetic engineering, in particular to a self-assembled protein cage nanoparticle epitope insertion site and application thereof in vaccine preparation. It is found that a foot-and-mouth disease virus antigen epitope is inserted between the 124 -125 amino acid of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 124 -125 amino acid is replaced with the foot-and-mouth disease virus antigen epitope, efficient and soluble expression of a target antigen in escherichia coli can be achieved, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized anti-foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a foot-and-mouth disease vaccine.

The invention discloses a monoclonal antibody of feline herpesvirus gB protein, an antigen epitope peptide recognized by the monoclonal antibody and application of the monoclonal antibody. The monoclonal antibody of the feline herpesvirus gB protein comprises an antibody heavy chain and an antibody light chain, wherein a variable region of the antibody light chain comprises a CDR1 consisting of an amino acid sequence as shown in SEQ ID NO.1, a CDR2 of which the amino acid sequence is QVS and a CDR3 consisting of an amino acid sequence as shown in SEQ ID NO.3; a variable region of the antibody heavy chain comprises a CDR1 composed of an amino acid sequence shown in SEQ ID NO.4, a CDR2 composed of an amino acid sequence shown in SEQ ID NO.2 and a CDR3 composed of an amino acid sequence shown in SEQ ID NO.5. According to the research, one specific monoclonal antibody is successfully prepared and obtained, the antigen epitope recognized by the specific monoclonal antibody is identified, and a biological foundation is laid for developing a specific detection reagent of FHV-1.

The present invention discloses an anti-sulfadiazine nano-antibody and its application, belonging to the field of nano-antibody technology. In order to provide a nano-antibody for detecting sulfadiazine that has a small molecular weight, strong penetrating power, good stability, strong antigen binding ability, and can recognize antigen epitopes that are difficult for conventional antibodies to recognize. The present invention provides a nano-antibody for detecting sulfadiazine, the amino acid sequence of CDR1 of the variable region of the nano-antibody is shown as SEQ ID NO.6, the amino acid sequence of CDR2 of the variable region of the nano-antibody is shown as SEQ ID NO.7, and the amino acid sequence of CDR3 of the variable region of the nano-antibody is shown as SEQ ID NO.8. The indirect competitive ELISA method established by the present invention is a simple, rapid, sensitive, and low-cost immunoassay method, which has great application prospects in the detection of sulfadiazine residues in animal-derived foods.

This invention discloses an antigen and vaccine preparation based on dominant Brucella epitopes, and their application, belonging to the field of recombinant subunit vaccine technology. The antigen is composed of CTL epitopes, HTL epitopes, and B-cell epitopes tandemly, and its amino acid sequence is shown in SEQ ID NO.1. Based on screened dominant CTL epitopes, HTL epitopes, and B-cell epitopes of the Omp25 and Omp31 outer membrane proteins, this invention constructs a novel antigen fusion polypeptide. The vaccine prepared based on this polypeptide effectively activates a significant dual immune response, enhancing cellular immunity while inducing the body to produce high levels of specific antibodies. It also provides good protection against organ damage caused by bacterial infection, offering better immune response and protective efficacy against Brucella, laying the foundation for the development of Brucella recombinant subunit vaccines.

The present invention discloses a recombinant porcine circovirus type 3 trimer protein, a preparation method and an application thereof. The present invention uses bioinformatics methods and resources to predict the B cell antigen epitopes and T cell antigen epitopes of the PCV3Cap protein. Taking into account the stability and immunogenicity of the antigen epitopes, a recombinant porcine circovirus type 3 trimer protein based on the PCV3Cap protein antigen epitope is designed, and its efficient soluble expression in Escherichia coli is achieved. The expressed recombinant porcine circovirus type 3 trimer protein can be mass-produced and purified by Ni-NTA affinity chromatography. The purified recombinant porcine circovirus type 3 trimer protein can assemble into a stable trimer structure. The subunit vaccine prepared using the recombinant porcine circovirus type 3 trimer protein can induce experimental pigs to produce a high level of antibodies and has a significant protective effect on the experimental pigs. The recombinant porcine circovirus type 3 trimer protein designed by the present invention provides a new idea for the development of PCV3 vaccine.

The invention relates to a pTau antigen compound of an AP205 or Lus protein nanoparticle carrier, a vaccine containing the pTau antigen compound as well as a preparation method and application of the pTau antigen compound. According to the pTau antigen compound disclosed by the invention, pTau antigen epitope peptide is efficiently loaded on a protein nanoparticle carrier by utilizing a specific SpyCatcher-SpyTag biological coupling system and is self-assembled to form a 180 / 60 polymer spherical structure, so that the pTau antigen epitope peptide is displayed on the surface of the spherical structure to form an ordered and repeated antigen array; therefore, an organism can be stimulated to generate specific immune response aiming at pTau protein to the greatest extent, and the immunogenicity is relatively high; the vaccine based on the pTau antigen compound can induce an organism to generate a high-titer pTau antibody, and cannot induce generation of T cell reaction aiming at pTau, so that the vaccine has relatively high safety.

The application discloses a tandem antigen epitope peptide of G protein of Paralichthys olivaceus rhabdovirus and application thereof, and belongs to the field of fish molecular immunology. The amino acid sequence of the tandem antigen epitope peptide is shown as SEQ ID NO:1. The preparation method of the application comprises the following steps: (1) first, analyzing the structural characteristics of HIRRV-G protein and predicting B cell antigen epitopes, and synthesizing the antigen epitopes with advantages based on the prediction results; (2) then, screening candidate peptide segments with high affinity through enzyme-linked immunosorbent assay; (3) sequentially connecting the high-affinity peptide segment sequences meeting the requirements by using a GPGPG linker, and cloning the connected sequences into a pET-28a prokaryotic expression vector, so that the tandem antigen epitope peptide is obtained after induced expression. Compared with the full-length G protein, the tandem antigen epitope peptide has smaller molecular weight, stronger stability and stronger hydrophilicity; the tandem antigen epitope peptide can induce a large amount of specific antibodies in fish bodies, and significantly reduces the mortality of fish infected by the virus. The tandem antigen epitope peptide can be used for the development of HIRRV diagnostic reagents and subunit vaccines.

The invention discloses an EB (Epstein-Barr) virus antigen with chimeric design and application thereof. The EB virus chimeric antigen provided by the invention is reasonably designed on the basis of structural biology, gL, gH and gp42 proteins of the EB virus are connected through a linker, and the chimeric designed antigen stably presents antigen epitopes of the three proteins at the same time, so that the production amplification process and quality control can be simplified while the vaccine immunogenicity is improved. The EB virus chimeric antigen can be used independently or in combination with other antigens, has high immunogenicity when being used as a vaccine or a vaccine component, can induce an immunized animal to generate a high-level neutralizing antibody, can be used for preparing a vaccine for preventing or treating EB virus infection, and can also be used as a reagent for detecting EB virus.

The present application relates to a 48E-scFv-Fc recombinant antibody with broad-spectrum activity against waterfowl parvovirus, a construction method and application thereof, the 48E-scFv-Fc recombinant antibody comprising a light chain variable region and a heavy chain variable region, and the amino acid sequences of the light chain variable region and the heavy chain variable region are shown as SEQ ID NO: 1-2. The present application provides a coding gene for encoding the recombinant antibody, which comprises a DNA sequence shown as SEQ ID NO: 3-4. The present application also provides a corresponding recombinant plasmid and a preparation method of the 48E-scFv-Fc recombinant antibody, etc. The 48E-scFv-Fc recombinant antibody can simultaneously recognize four waterfowl parvoviruses of cGPV, MDPV, MDGPV and SBDSV, and has a good application prospect in immunological detection of waterfowl parvovirus infection, antigen epitope research, passive immunization preparation development and broad-spectrum antibody drug research, etc.

The invention relates to the technical field of biology, in particular to a helicobacter pylori antibody typing reagent combination as well as a preparation method and application of the helicobacter pylori antibody typing reagent combination. Comprising an acridinium ester mouse anti-human IgG complex solution, a biotin-Ure recombinant protein complex solution, a biotin-CVfp fusion protein complex solution and a streptavidin magnetic bead mother solution. The biotin-Ure recombinant protein complex liquid is obtained by labeling Ure recombinant protein with biotin, and the amino acid sequence of the Ure recombinant protein is as shown in SEQ ID No. 1; the biotin-CVfp fusion protein complex liquid is obtained by labeling CVfp fusion protein with biotin, the CVfp fusion protein carries out fusion expression on antigen epitopes of CagA and VacA, and the amino acid sequence of the CVfp fusion protein is shown as SEQ ID No.2. The problems that at present, Hp virulence factor typing detection indexes are complex, reagent cost is high, and detection flux is low are solved.